Billionaire George Soros Stock Portfolio: Top 10 Stock Picks

2. AstraZeneca PLC (NASDAQ:AZN)

Soros Fund Management’s stake as of Q3: $206.67 million

AstraZeneca PLC (NASDAQ:AZN) stands out as a pharmaceutical industry leader, particularly known for its work in cancer therapies and treatments for rare conditions. The company’s track record of medical breakthroughs has cemented its position in healthcare.

A minor uptick in Leerink Partners’ price target to $87 followed AstraZeneca’s strong third-quarter performance, with revenue reaching $13.565 billion – exceeding projections by 4%. While their cancer drug portfolio showed mixed results, with Tagrisso, Calquence, and Lynparza beating expectations but Imfinzi/Imjudo falling short, their respiratory drug Symbicort posted impressive 21% growth, complemented by Ultomiris’s 7% gain.

The company is now making a significant push into the American market, allocating $3.5 billion for expanded manufacturing and research operations. Despite increased net debt of $3.8 billion from this expansion, acquisitions, and shareholder dividends, AstraZeneca PLC (NASDAQ:AZN) remains confident in its future. The company maintains its strategic objectives of achieving an operating margin above 35% by 2026 and generating $80 billion in annual revenue by 2030.